

Marie-JosÃ© Kersten

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6656335/publications.pdf>

Version: 2024-02-01

119
papers

4,018
citations

186209

28
h-index

138417

58
g-index

122
all docs

122
docs citations

122
times ranked

4736
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 555-567. | 0.8 | 82 |
| 2 | Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 40-51. | 0.8 | 22 |
| 3 | Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018. <i>British Journal of Haematology</i> , 2022, 196, 660-669. | 1.2 | 7 |
| 4 | The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in ¹⁸ F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1424-1430. | 2.8 | 20 |
| 5 | Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison. <i>Leukemia and Lymphoma</i> , 2022, 63, 845-854. | 0.6 | 6 |
| 6 | T-cell subset composition and functionality in patients with Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-5. | 0.6 | 3 |
| 7 | Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 640-654. | 13.9 | 586 |
| 8 | Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy. <i>Journal of Neurology</i> , 2022, 269, 3700-3705. | 1.8 | 8 |
| 9 | Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era. <i>Leukemia</i> , 2022, 36, 1416-1420. | 3.3 | 3 |
| 10 | Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989-2018. <i>Blood Cancer Journal</i> , 2022, 12, 38. | 2.8 | 6 |
| 11 | Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams. <i>Quality of Life Research</i> , 2022, 31, 2357-2366. | 1.5 | 5 |
| 12 | Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach. <i>Cancers</i> , 2022, 14, 1857. | 1.7 | 6 |
| 13 | Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression. <i>Leukemia and Lymphoma</i> , 2022, 63, 1070-1079. | 0.6 | 8 |
| 14 | Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. <i>Haematologica</i> , 2021, 106, 1129-1137. | 1.7 | 57 |
| 15 | Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017. <i>Leukemia</i> , 2021, 35, 494-505. | 3.3 | 11 |
| 16 | Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989-2016. <i>Leukemia</i> , 2021, 35, 1683-1695. | 3.3 | 8 |
| 17 | Conditional relative survival among patients with follicular lymphoma: a population-based study in the Netherlands. <i>Blood Cancer Journal</i> , 2021, 11, 12. | 2.8 | 1 |
| 18 | WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes. <i>American Journal of Hematology</i> , 2021, 96, E218-E222. | 2.0 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).. Journal of Clinical Oncology, 2021, 39, 7535-7535. | 0.8 | 2 |
| 20 | Conditional relative survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma in the Netherlands. Blood Cancer Journal, 2021, 11, 87. | 2.8 | 1 |
| 21 | Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem. , 2021, 9, e002916. | | 29 |
| 22 | Professor Anton Hagenbeek 1948â€“2021: Father of MRD and lymphoma expert. Bone Marrow Transplantation, 2021, 56, 2038-2039. | 1.3 | 0 |
| 23 | Efficacy and safety of <sc>CD19</sc>â€directed <sc>CARâ€T</sc> cell therapies in patients with relapsed/refractory aggressive Bâ€cell lymphomas: Observations from the <sc>JULIET</sc>, <sc>ZUMA</sc>â€1, and <sc>TRANSCEND</sc> trials. American Journal of Hematology, 2021, 96, 1295-1312. | 2.0 | 107 |
| 24 | Frequent mutated <i>B2M</i>, <i>EZH2</i>, <i>IRF8</i>, and <i>TNFRSF14</i> in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. Blood Advances, 2021, 5, 3760-3775. | 2.5 | 11 |
| 25 | EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for WaldenstrÃ¶m's Macroglobulinemia. HemaSphere, 2021, 5, e634. | 1.2 | 2 |
| 26 | Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view. Expert Review of Anticancer Therapy, 2021, 21, 1-12. | 1.1 | 1 |
| 27 | Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncology, The, 2021, 22, 1403-1415. | 5.1 | 222 |
| 28 | Efficacy and safety of daratumumab combined with all-<i>trans</i> retinoic acid in relapsed/refractory multiple myeloma. Blood Advances, 2021, 5, 5128-5139. | 2.5 | 22 |
| 29 | Conditional relative survival in WaldenstrÃ¶m's macroglobulinaemia: a populationâ€based study in The Netherlands. British Journal of Haematology, 2021, , . | 1.2 | 2 |
| 30 | Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data. Blood, 2021, 138, 879-879. | 0.6 | 3 |
| 31 | Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. Blood, 2021, 138, 131-131. | 0.6 | 8 |
| 32 | Evaluating Patients' Preferences Regarding Treatment Options for WaldenstrÃ¶m's Macroglobulinemia, a Discrete-Choice-Experiment. Blood, 2021, 138, 835-835. | 0.6 | 2 |
| 33 | Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018. Blood Cancer Journal, 2021, 11, 179. | 2.8 | 5 |
| 34 | First-Line Treatment and Survival of Stage I(E) Peripheral T-Cell Lymphoma in the Netherlands; A Nationwide Population-Based Cohort Study. Blood, 2021, 138, 1381-1381. | 0.6 | 1 |
| 35 | Global WaldenstrÃ¶m's Macroglobulinemia Patient-Derived Data Registry, Whimsical, Highlights Real-World Treatment Outcomes and COVID-19 Data. Blood, 2021, 138, 1343-1343. | 0.6 | 0 |
| 36 | Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study. Blood, 2021, 138, LBA-6-LBA-6. | 0.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents. Hematology American Society of Hematology Education Program, 2021, 2021, 240-246. | 0.9 | 5 |
| 38 | <i>MYD88</i> mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. Haematologica, 2020, 105, 424-434. | 1.7 | 55 |
| 39 | Tailoring the amount of treatment information to cancer patientsâ€™ and survivorsâ€™ preferences: Effects on patient-reported outcomes. Patient Education and Counseling, 2020, 103, 514-520. | 1.0 | 31 |
| 40 | Provider caring and structuring treatment information to improve cancer patientsâ€™ recall: Does it help?. Patient Education and Counseling, 2020, 103, 55-62. | 1.0 | 14 |
| 41 | Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data. Medicine and Science in Sports and Exercise, 2020, 52, 303-314. | 0.2 | 50 |
| 42 | Acalabrutinib monotherapy in patients with WaldenstrÃ¶m macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematology, 2020, 7, e112-e121. | 2.2 | 119 |
| 43 | Physical activity in patients with cancer: self-report versus accelerometer assessments. Supportive Care in Cancer, 2020, 28, 3701-3709. | 1.0 | 18 |
| 44 | Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica, 2020, 105, 297-316. | 1.7 | 230 |
| 45 | Consensus treatment recommendations from the tenth International Workshop for WaldenstrÃ¶m Macroglobulinaemia. Lancet Haematology, 2020, 7, e827-e837. | 2.2 | 96 |
| 46 | CD19-directed CAR T-cell therapy in B-cell NHL. Current Opinion in Oncology, 2020, 32, 408-417. | 1.1 | 26 |
| 47 | The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population-based study. EJHaem, 2020, 1, 489-497. | 0.4 | 5 |
| 48 | The Successful Return-To-Work Questionnaire for Cancer Survivors (I-RTW_CS): Development, Validity and Reproducibility. Patient, 2020, 13, 567-582. | 1.1 | 11 |
| 49 | HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma. HemaSphere, 2020, 4, e325. | 1.2 | 2 |
| 50 | Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. Haematologica, 2020, 105, 2805-2812. | 1.7 | 30 |
| 51 | Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Advances, 2020, 4, 560-572. | 2.5 | 88 |
| 52 | Whimsical (Waldenstrom's Macroglobulinemia Study Involving CART-wheel): A Global Patient-Derived Data Registry Capturing Treatment, Quality of Life and COVID-19 Data. Blood, 2020, 136, 30-31. | 0.6 | 1 |
| 53 | Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial. Blood, 2020, 136, 1-3. | 0.6 | 18 |
| 54 | Bendamustine Plus Rituximab for the Treatment of WaldenstrÃ¶m Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing. Blood, 2020, 136, 10-11. | 0.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Fatigue, anxiety, depression and quality of life in kidney transplant recipients, haemodialysis patients, patients with a haematological malignancy and healthy controls. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 833-838. | 0.4 | 52 |
| 56 | Rituximab+PECC induction followed by ⁹⁰ Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study. <i>British Journal of Haematology</i> , 2019, 187, 347-355. | 1.2 | 8 |
| 57 | MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications. <i>Haematologica</i> , 2019, 104, 2337-2348. | 1.7 | 48 |
| 58 | Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. <i>Haematologica</i> , 2019, 104, 2274-2282. | 1.7 | 27 |
| 59 | Rare but Serious: Ibrutinib Induced Liver Failure. <i>HemaSphere</i> , 2019, 3, e307. | 1.2 | 5 |
| 60 | Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRAVE study. <i>Haematologica</i> , 2019, 104, e151-e153. | 1.7 | 27 |
| 61 | Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroglobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial. <i>Blood</i> , 2019, 134, 344-344. | 0.6 | 7 |
| 62 | Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel. <i>Blood</i> , 2019, 134, 2883-2883. | 0.6 | 15 |
| 63 | KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. <i>Blood</i> , 2019, 134, 754-754. | 0.6 | 18 |
| 64 | Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). <i>Blood</i> , 2019, 134, 242-242. | 0.6 | 8 |
| 65 | Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. <i>Blood</i> , 2019, 134, 4103-4103. | 0.6 | 24 |
| 66 | Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up. <i>Blood</i> , 2019, 134, 3308-3308. | 0.6 | 3 |
| 67 | Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7558-7558. | 0.8 | 7 |
| 68 | Effective Information Provision About the Side Effects of Treatment for Malignant Lymphoma: Protocol of a Randomized Controlled Trial Using Video Vignettes. <i>JMIR Research Protocols</i> , 2019, 8, e12453. | 0.5 | 5 |
| 69 | High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. <i>Blood</i> , 2018, 131, 2086-2089. | 0.6 | 69 |
| 70 | Chimeric Antigen Receptor T Cell Therapy. <i>HemaSphere</i> , 2018, 2, e18. | 1.2 | 30 |
| 71 | Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e170-e180. | 2.2 | 44 |
| 72 | Final results of a phase 1b study of the safety and efficacy of the PI3K inhibitor acalısib (GS-9820) in relapsed/refractory lymphoid malignancies. <i>Blood Cancer Journal</i> , 2018, 8, 16. | 2.8 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Clinicopathological characteristics of T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies: a single-center case series of 25 patients and a review of the literature. <i>Haematologica</i> , 2018, 103, 486-496. | 1.7 | 9 |
| 74 | Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1190-1200. | 3.0 | 72 |
| 75 | Developing a digital communication training tool on information-provision in oncology: uncovering learning needs and training preferences. <i>BMC Medical Education</i> , 2018, 18, 220. | 1.0 | 21 |
| 76 | Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. <i>Lancet Haematology</i> , 2018, 5, e479-e492. | 2.2 | 25 |
| 77 | Successful Treatment of MYC rearrangement Positive Large B Cell Lymphoma Patients with R-CHOP21 Plus Lenalidomide: Results of a Multicenter Phase II HOVON Trial. <i>Blood</i> , 2018, 132, 786-786. | 0.6 | 8 |
| 78 | Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. <i>Blood</i> , 2018, 132, 1684-1684. | 0.6 | 28 |
| 79 | Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7501-7501. | 0.8 | 11 |
| 80 | ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7585-TPS7585. | 0.8 | 18 |
| 81 | Health-related physical fitness in patients with multiple myeloma or lymphoma recently treated with autologous stem cell transplantation. <i>Journal of Science and Medicine in Sport</i> , 2017, 20, 116-122. | 0.6 | 11 |
| 82 | Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM consensus panel. <i>British Journal of Haematology</i> , 2017, 176, 728-742. | 1.2 | 58 |
| 83 | Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017, 102, 1413-1423. | 1.7 | 39 |
| 84 | Validation and Refinement of Prediction Models to Estimate Exercise Capacity in Cancer Survivors Using the Steep Ramp Test. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, 2167-2173. | 0.5 | 15 |
| 85 | Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. <i>Cancer Treatment Reviews</i> , 2017, 52, 91-104. | 3.4 | 398 |
| 86 | Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. <i>Haematologica</i> , 2017, 102, 43-51. | 1.7 | 112 |
| 87 | CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. <i>Haematologica</i> , 2017, 102, e452-e455. | 1.7 | 22 |
| 88 | Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. <i>Hematological Oncology</i> , 2017, 35, 497-503. | 0.8 | 36 |
| 89 | Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study. <i>PLoS ONE</i> , 2017, 12, e0181313. | 1.1 | 64 |
| 90 | Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 574-583. | 0.6 | 69 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 161-168. | 0.7 | 5 |
| 92 | Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation. Transplantation Direct, 2016, 2, e48. | 0.8 | 68 |
| 93 | Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia. Haematologica, 2016, 101, e111-e115. | 1.7 | 30 |
| 94 | Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial. Blood, 2016, 128, 1141-1141. | 0.6 | 7 |
| 95 | High Rates of Minimal Residual Disease-Negative (MRD ⁺) Complete Responses (CR) in Adult and Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials. Blood, 2016, 128, 2803-2803. | 0.6 | 24 |
| 96 | A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma. Blood, 2016, 128, 4199-4199. | 0.6 | 1 |
| 97 | Tumor Specific Glycosylated CD43 Is a Novel and Highly Specific Target for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2016, 128, 1646-1646. | 0.6 | 0 |
| 98 | Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood, 2015, 125, 449-456. | 0.6 | 60 |
| 99 | Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood, 2015, 125, 2306-2309. | 0.6 | 79 |
| 100 | Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival. Haematologica, 2015, 100, e508-e510. | 1.7 | 10 |
| 101 | Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial. Blood, 2015, 126, 27-27. | 0.6 | 28 |
| 102 | Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study. Blood, 2015, 126, 339-339. | 0.6 | 15 |
| 103 | Defining the Incidence, Pathology and Clinical Outcomes of Kidney Disease Related to Waldenstrom's Macroglobulinemia and IgM MGUS. Blood, 2015, 126, 3926-3926. | 0.6 | 2 |
| 104 | Precision medicine in diffuse large B-cell lymphoma: hitting the target. Haematologica, 2015, 100, 989-93. | 1.7 | 19 |
| 105 | Combined Inhibition of mTOR and DNA-PK Blocks Survival, Adhesion, Proliferation and Chemoresistance in Primary Chronic Lymphocytic Leukemia (CLL) Cells. Blood, 2014, 124, 1981-1981. | 0.6 | 3 |
| 106 | Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma. Blood, 2014, 124, 4735-4735. | 0.6 | 0 |
| 107 | Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform Î± and Î³ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation. Blood, 2014, 124, 4691-4691. | 0.6 | 1 |
| 108 | The Impact of Allogeneic Stem Cell Transplantation As Part of First Line Treatment on Outcome of Patients with Multiple Myeloma Depends on the Method of Analysis. Blood, 2014, 124, 1209-1209. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies. Blood, 2013, 122, 2881-2881. | 0.6 | 7 |
| 110 | SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study. Blood, 2013, 122, 86-86. | 0.6 | 8 |
| 111 | Radioimmunotherapy in follicular lymphoma: Some like it hot. Transfusion and Apheresis Science, 2011, 44, 173-178. | 0.5 | 7 |
| 112 | Psychometric properties of two physical activity questionnaires, the AQuAA and the PASE, in cancer patients. BMC Medical Research Methodology, 2011, 11, 30. | 1.4 | 47 |
| 113 | High Incidence of Peripheral Blood Plasmacytosis In Patients with Dengue Virus Infection: a Prospective Study. Blood, 2010, 116, 2772-2772. | 0.6 | 0 |
| 114 | Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma.. Blood, 2009, 114, 1790-1790. | 0.6 | 0 |
| 115 | CMV-Associated Expansion of CD8+CD45RA+CD27+ T-Cells in Patients with B-Cell Malignancies.. Blood, 2007, 110, 3592-3592. | 0.6 | 0 |
| 116 | In Vivo Tumor Dynamic Studies in Stable CLL Show an Association between CLL Turnover Rates and IgVH Mutational Status and Provide Evidence That the Bone Marrow Is Not a Major Site of Neoplastic Cell Generation.. Blood, 2007, 110, 1128-1128. | 0.6 | 0 |
| 117 | Gene Expression Profiling Can Predict Responsiveness to Chemotherapy in Patients with Transformation of Follicular Lymphoma.. Blood, 2006, 108, 823-823. | 0.6 | 0 |
| 118 | Gene Expression Profiles Are Best Suited To Assess Present Though Not Future Clinical Aggressiveness in Follicular Lymphoma.. Blood, 2004, 104, 698-698. | 0.6 | 1 |
| 119 | Carboxy Terminal Variants of Epstein-Barr Virus Encoded Latent Membrane Protein 1 during Long-Term Human Immunodeficiency Virus Infection: Reliable Markers for Individual Strain Identification. Journal of Infectious Diseases, 1999, 179, 240-244. | 1.9 | 74 |